Quantcast
Last updated on April 23, 2014 at 11:02 EDT

Latest Stemline Therapeutics Inc. Stories

2013-01-07 08:30:25

NEW YORK, Jan. 7, 2013 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, announced today that a second heavily pre-treated patient with a drug-refractory and recurrent blastic plasmacytoid dendritic cell neoplasm (BPDCN) achieved a complete response (CR) following treatment with a single cycle of Stemline's lead therapeutic, SL-401. BPDCN is a highly aggressive...

2012-11-08 08:35:33

NEW YORK, Nov. 8, 2012 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, announced today that a heavily pre-treated patient with a drug-refractory and recurrent blastic plasmacytoid dendritic cell neoplasm (BPDCN) achieved a complete response (CR) following treatment with Stemline's SL-401. BPDCN is a rare and aggressive hematologic cancer which is generally...

2012-04-18 02:28:30

NEW YORK, April 18, 2012 /PRNewswire/ -- Stemline Therapeutics, Inc. announced that trial results of two clinical studies of direct injection synthetic peptide vaccine, now being developed as SL-701, in both adults and children with advanced brain cancer were selected for late-breaking presentations at the Annual Meeting of the American Association for Cancer Research (AACR) held from March 31 to April 4, 2012 in Chicago, IL. SL-701 is comprised of synthetic peptides corresponding to epitopes...

2012-04-03 02:26:51

NEW YORK, April 3, 2012 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock. The offering size and the estimated price range of the offering have not yet been determined. All shares proposed to be included...

2012-03-15 07:30:00

NEW YORK, March 15, 2012 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, today announced that Kevin Buchi has joined its Board of Directors. Since serving as Chief Executive Officer of Cephalon, Inc. through its $6.8 billion acquisition by Teva Pharmaceutical Industries (Nasdaq: TEVA) in October 2011, Mr. Buchi has served as Corporate Vice President, Global...

2012-01-09 07:30:00

NEW YORK, Jan. 9, 2012 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology therapeutics that target cancer stem cells (CSCs), today announced that Eric K. Rowinsky, M.D. will join the Company as Executive Vice President, Chief Medical Officer and Head of Research and Development. Dr. Rowinsky will oversee the development and registration efforts for the Company's two clinical stage drug candidates, SL-401 and SL-701, as well as its...

2011-12-12 07:30:00

NEW YORK, Dec. 12, 2011 /PRNewswire/ -- Stemline Therapeutics, Inc. today announced that Ivan Bergstein, MD, the Company's Chief Executive Officer, is scheduled to present at the Oppenheimer 22nd Annual Healthcare Conference on Wednesday, December 14, 2011 at 10:15 a.m. ET at the Waldorf Astoria Hotel in New York City. About Stemline Therapeutics, Inc. Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells...

2011-12-08 07:30:00

NEW YORK, Dec. 8, 2011 /PRNewswire/ -- Stemline Therapeutics, Inc. today announced that two studies of SL-401, a clinical stage therapeutic being developed in patients with myeloid malignancies, have also demonstrated preclinical activity against a variety of lymphoid malignancies and have been selected for presentation at the upcoming 53rd Annual Meeting of the American Society of Hematology (ASH) to be held in San Diego, CA from December 10-13, 2011. One study demonstrates that...

2011-06-06 07:00:00

NEW YORK, June 2, 2011 /PRNewswire/ -- Stemline Therapeutics, Inc. today announced that clinical results from a multi-epitope brain cancer vaccine, that Stemline has licensed from the University of Pittsburgh (Pitt) and is further developing as SL-701, will be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL, on Monday, June 6, 2011 at 1 PM CT. Dr. Hideho Okada, Associate Professor of Neurological Surgery at Pitt, will deliver the presentation....

2011-03-09 07:30:00

NEW YORK, March 9, 2011 /PRNewswire/ -- Stemline Therapeutics, Inc. today announced that SL-401, the Company's lead compound, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML). SL-401 has completed a multi-center Phase I/II clinical trial in AML where it has demonstrated single agent efficacy, including two durable complete responses (CRs), multiple blast reductions and disease stabilizations, and an...